You are here

AUREOGEN, INC.

Company Information
Address
4717 CAMPUS DR STE 2300
KALAMAZOO, MI 49008-5620
United States



Information

UEI: NETHCTLPJSR4

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel Antifungals by Engineering the AbA NRPS gene

    Amount: $481,481.00

    DESCRIPTION (provided by applicant): The continuing increase in the number of surgery, transplantation, cancer and other immunocompromized patients, that need treatment for fungal infections, together ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  2. Generation of novel HCV drugs through engineereing of the cssA gene

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): HCV infections are a prevalent and growing health problem. It is estimated that as many as 2% of the US population, and 2.5% of the population world-wide, are infe ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  3. Generation of novel drugs against drug resistant bacteria through engineering of

    Amount: $286,746.00

    DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant bacterial infections has increased drastically in recent years. What started as a problem primarily associ ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  4. A Bacitracin derivative for systemic use

    Amount: $381,116.00

    DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant infections has increased drastically in recent years. What started as a problem primarily associated with ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  5. Novel Antifungals by Engineering the AbA NRPS gene

    Amount: $1,978,700.00

    DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides consti ...

    SBIRPhase II2006Department of Health and Human Services National Institutes of Health
  6. Novel Antifungals by Engineering the AbA NRPS gene

    Amount: $162,982.00

    DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government